# Page 99 Audit — Methods: Table 2 PICOM Clinical Questions (90 Spans)

## Page Identity
- **PDF page**: S98 (Methods for Guideline Development — www.kidney-international.org)
- **Content**: Table 2 — Clinical questions and systematic review topics in PICOM format (Population, Intervention, Comparator, Outcome, Methods) for 6 clinical questions covering RAS inhibitors, dual RAS, SGLT2i, MRA/DRI, potassium binders, antiplatelet therapy
- **Clinical tier**: T3 (Informational — methodology table defining review scope)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: NO

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 52 |
| T1 (Patient Safety) | 2 |
| T2 (Clinical Accuracy) | 50 |
| T3 (Informational) | 0 |
| Channels present | B (Drug Dictionary), D (Table Decomp), F (NuExtract LLM) |
| Genuinely correct T1 | 0 |
| Genuinely correct T2 | 0 |
| Tier accuracy | 0% (0/52) |
| Disagreements | 0 |
| Review Status | FINAL: 15 ADDED, 8 CONFIRMED, 82 REJECTED |
| Cross-Check | 2026-02-25 — Count corrected 90→52, T1 5→2, T2 85→50; verified against raw extraction data |
| Raw PDF Cross-Check | 2026-02-28 — 8 agent spans CONFIRMED, 82 rejected (D channel table cell explosion), 15 gaps added |
| Audit Date | 2026-02-25 (revised) |

## Channel Breakdown
| Channel | Count | Confidence | Content |
|---------|-------|------------|---------|
| D (Table Decomp) | 87 | 92% | Table 2 cell values (questions, populations, interventions, outcomes, references) |
| B (Drug Dictionary) | 2 | 100% | "Mineralocorticoid receptor antagonists" (T1) + "RAS inhibitors" (T2) |
| F (NuExtract LLM) | 1 | 90% | HTML comment artifact |

## T1 Spans (5) — ALL MISTIERED

| # | Text | Channel | Conf | Correct Tier | Issue |
|---|------|---------|------|-------------|-------|
| 1 | "In patients with T2D and CKD, what are the effects of SGLT2i on clinically relevant outcomes and clinically relevant har..." | D | 92% | T3 | PICOM clinical question text |
| 2 | "Mineralocorticoid receptor antagonists or direct renin inhibitors" | D | 92% | T3 | Table 2 "Intervention" cell |
| 3 | "Dual RAS inhibition (ACEi and ARB)" | D | 92% | T3 | Table 2 "Intervention" cell |
| 4 | "Mono RAS inhibition (ACEi or ARB)" | D | 92% | T3 | Table 2 "Comparator" cell |
| 5 | "Mineralocorticoid receptor antagonists" | B | 100% | T3 | Drug class name from Table 2 context |

**Analysis**: T1 classification triggered by drug class names (SGLT2i, MRA, ACEi, ARB) appearing in the PICOM table's Intervention/Comparator columns. These are methodology scope definitions, not prescribing directives or safety warnings.

## T2 Spans (85) — ALL MISTIERED, Massive Duplication

### Duplication Analysis
| Extracted Text | Occurrences | Source |
|---------------|-------------|--------|
| "reviews" | 14× | "Cochrane systematic reviews" column, truncated |
| "Critical and important outcomes listed in Table 1" | 8× | "Outcomes" column for each clinical question |
| "Adults with CKD (G1-G5, G5D) and diabetes (T1D and T2D)" | 8× | "Population" column repeated per question |
| "Adults with CKD (G1-G5, G5D, G1T-G5T) and diabetes (T2D)" | 2× | Population variant for SGLT2i/transplant |
| "Additional outcomes: AKI, hyperkalemia" | 4× | Outcome additions per question |
| "Standard of care/placebo" | 3× | Comparator column |
| "Cochrane systematic reviews" | 2× | Study design column |
| "Guideline chapter 1" | 2× | Chapter reference column |
| Strippoli et al. citation | 3× | Cochrane reference (same study) |
| Supplementary table references | 5× | SoF table references |

**85 spans total, but only ~15 unique text values** — the D channel extracted every cell of Table 2's 6 clinical questions × 8 columns, creating massive duplication.

### Notable D Channel Content
- Clinical question texts (6 unique, long-form PICOM questions)
- Population definitions with CKD staging (G1-G5, G5D, G1T-G5T)
- "Long-term harms: hypoglycemia, lactic acidosis, amputation, bone fractures" — SGLT2i harm outcomes
- "Long-term harms: systematic review of observational studies" — study design note
- "(Continued on following page)" — pagination marker extracted as content

### F Channel HTML Artifact — 6th Occurrence
`<!-- PAGE 99 -->` at 90% confidence. Running tally: pages 91, 92, 94, 95, 98, 99.

### B Channel
"RAS inhibitors" extracted at 100% confidence from the clinical question text. Drug class name in methodology context.

## PDF Source Content Analysis

### Content Present on Page
**Table 2** — PICOM format for 6 clinical questions (partial, continues on next page):

1. **RAS inhibitors** (Ch1): ACEi and ARB vs standard care/placebo
2. **Dual vs Mono RAS inhibition** (Ch1): Dual (ACEi+ARB) vs Mono (ACEi or ARB)
3. **SGLT2i** (Ch1): SGLT2i vs standard care/placebo — includes long-term harms
4. **MRA/DRI** (Ch1): MRA or DRI vs standard care or RAS inhibition alone
5. **Potassium binders**: Potassium binders vs standard care for chronic hyperkalemia
6. **Antiplatelet therapy**: Antiplatelet vs... (continued on following page)

Each question includes: Population, Intervention, Comparator, Outcomes, Study design, Cochrane reviews, SoF tables

### What Should Have Been Extracted
| Content | Correct Tier | Extracted? |
|---------|-------------|------------|
| Table 2 structure (6 PICOM questions) | T3 | Partially (cells extracted, no structure) |
| "Long-term harms: hypoglycemia, lactic acidosis, amputation, bone fractures" | T3 | YES (D 92%, mistiered as T2) |
| Cochrane review citations | T3 | YES (D 92%, mistiered as T2) |
| Population staging (G1-G5 CKD) | T3 | YES (D 92%, mistiered as T2) |

## Cross-Page Patterns

### D Channel Table Decomposition — Methods Section
Page 99 (90 spans) follows the same pattern as page 93 (338 spans): the D channel treats structured tables as extractable clinical content. For methods tables, this creates massive noise:
- Every repeated column value becomes a separate span
- No semantic grouping of question-answer pairs
- Cell-level extraction without row/column context

### Methods Section Running Total (Pages 98-99)
| Page | Spans | Tier Accuracy | Content |
|------|-------|--------------|---------|
| 98 | 6 | 0% | Table 1 outcomes + methods prose |
| 99 | 90 | 0% | Table 2 PICOM questions |
| **Total** | **96** | **0%** | All methodology — zero clinical risk |

## Quality Assessment

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Extraction completeness | LOW | Table cells without structure or context |
| Tier accuracy | 0% | All 90 spans should be T3 or NOISE |
| Clinical safety risk | NONE | Methods section — PICOM scope definitions |
| Channel diversity | LOW | 97% D channel |
| Noise level | EXTREME | 90 spans for a methodology table, 85% are duplicates |
| Pipeline bugs | 1 | HTML comment artifact (6th occurrence) |

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. Entire page is a methodology table defining the systematic review scope. No patient-facing clinical content.

---

## Raw PDF Cross-Check (2026-02-28)

### Pre-Review State
- **Total spans**: 90
- **ADDED**: 0
- **PENDING**: 2 (population definition, additional outcomes)
- **CONFIRMED**: 6 (from earlier bulk audit: Dual RAS, Mono RAS, MRA/DRI, Long-term harms, 2 population variants)
- **REJECTED**: 82 (D channel table cell explosion — "reviews" ×14, population strings ×12, outcome refs ×9, etc.)

### Agent Spans CONFIRMED (2 — from PENDING)
| # | ID | Text | Note |
|---|-----|------|------|
| 1 | `441f20e8` | Adults with CKD (G1-G5, G5D) and diabetes (T1D and T2D) | Table 2 Population row — valid KB-16 reference |
| 2 | `29cfd659` | Additional outcomes: AKI, hyperkalemia | Table 2 supplementary outcomes — valid KB-4 Safety |

### Previously CONFIRMED (6 — from bulk audit)
| # | ID | Text | Note |
|---|-----|------|------|
| 1 | `6f3368f2` | Mono RAS inhibition (ACEi or ARB) | Table 2 Comparator — Question 2 |
| 2 | `9b92826e` | Adults with CKD (G1-G5, G5D, G1T-G5T) and chronic hyperkalemia and diabetes (T1D and T2D) | Table 2 Population — Question 5 |
| 3 | `dd3f0098` | Long-term harms: hypoglycemia, lactic acidosis, amputation, bone fractures | Table 2 Outcomes — SGLT2i harms |
| 4 | `10570f44` | Mineralocorticoid receptor antagonists or direct renin inhibitors | Table 2 Intervention — Question 4 |
| 5 | `383e587e` | Adults with CKD (G1-G5, G5D, G1T-G5T) and diabetes (T2D) | Table 2 Population — Question 3 (SGLT2i) |
| 6 | `9eac3872` | Dual RAS inhibition (ACEi and ARB) | Table 2 Intervention — Question 2 |

### Gaps Added (15) — Exact PDF Text

| # | Gap Text (truncated) | Note |
|---|----------|------|
| G99-A | Do RAS inhibitors improve clinically relevant outcomes and reduce clinically relevant harms in patients with diabetes and CKD? Population: Adults with CKD (G1-G5, G5D)... | PICOM Question 1 — RAS inhibitors |
| G99-B | Strippoli et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;CD006257. | Cochrane citation — RAS inhibitors |
| G99-C | Does dual RAS inhibition compared to mono RAS inhibition improve clinically relevant outcomes... | PICOM Question 2 — Dual vs Mono RAS |
| G99-D | In patients with T2D and CKD, what are the effects of SGLT2i on clinically relevant outcomes and clinically relevant harms?... Long-term harms: hypoglycemia, lactic acidosis, amputation, bone fractures. | PICOM Question 3 — SGLT2i |
| G99-E | Lo et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018;9:CD011798. Lo et al. Glucose-lowering agents... 2017;2:CD009966. | Cochrane citations — SGLT2i |
| G99-F | Does the addition of medication blocking the action of aldosterone on RAS compared to standard of care or RAS inhibition alone improve clinically important outcomes... | PICOM Question 4 — Aldosterone blockade MRA/DRI |
| G99-G | Andad et al. Direct renin inhibitors... Cochrane Database Syst Rev. 2013:9;CD010724. Bolignano et al. Aldosterone antagonists... 2014;CD007004. | Cochrane citations — MRA/DRI |
| G99-H | In patients with CKD with chronic hyperkalemia and diabetes, compared to usual care, does the use of potassium binders improve clinically relevant outcomes... | PICOM Question 5 — Potassium binders |
| G99-I | Natale et al. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6:CD013165. | Cochrane citation — Potassium binders |
| G99-J | Do antiplatelet therapies improve clinically relevant outcomes and reduce clinically relevant harms in patients with diabetes and CKD?... Intervention: Antiplatelet therapy. | PICOM Question 6 — Antiplatelet (partial, continues next page) |
| G99-K | Table 2 | Clinical questions and systematic review topics in the PICOM format. Guideline chapter 1: Comprehensive care in patients with diabetes and CKD. | Table 2 header + chapter scope |
| G99-L | Supplementary Tables S4, S5, S29, S30, and S34 | SoF references — RAS inhibitors |
| G99-M | Supplementary Tables S6, S32, S33 | SoF references — SGLT2i |
| G99-N | Supplementary Tables S7-S9, S32-S35 | SoF references — MRA/DRI |
| G99-O | Supplementary Tables S42-S46 | SoF references — Potassium binders |

### Post-Review State
- **Total spans**: 105
- **ADDED**: 15 (all new gaps)
- **CONFIRMED**: 8 (6 from bulk audit + 2 from PENDING)
- **REJECTED**: 82 (D channel table cell noise)
- **P2-ready facts**: 23

### KB Routing
| Gap | Target KB | Rationale |
|-----|-----------|-----------|
| G99-A, G99-C | KB-1 (Dosing) + KB-4 (Safety) | RAS inhibitor clinical questions — ACEi/ARB interventions |
| G99-D | KB-1 (Dosing) + KB-4 (Safety) | SGLT2i clinical question with long-term harms |
| G99-F | KB-1 (Dosing) + KB-4 (Safety) | Aldosterone blockade MRA/DRI question |
| G99-H | KB-1 (Dosing) + KB-4 (Safety) | Potassium binders for hyperkalemia |
| G99-J | KB-4 (Safety) | Antiplatelet therapy question |
| G99-B, G99-E, G99-G, G99-I | KB-7 (Terminology) | Cochrane systematic review citations |
| G99-K–O | KB-7 (Terminology) | Table header, SoF table references |
| All 8 confirmed spans | KB-16 (Monitoring) + KB-4 (Safety) | Population definitions, interventions, outcome categories |

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Raw PDF Cross-Check**: 2026-02-28 (claude-auditor via API)
- **Page in sequence**: 99 of 126
